Coronavirus disease 2019 (COVID-19) has not affected Florida as much as previously thought; despite emergency use authorization, remdesivir distribution is confusing many; a CDC report meant to provide guidance on reopening the country will apparently not be released.
Numbers coming out of the Sunshine State show Florida is staying ahead of the coronavirus disease 2019 (COVID-19) pandemic, reports The Hill. With just 3.9% of COVID-19 cases (1471 of 37,439) resulting in death, the state ranks eighth in confirmed cases of the disease even though it has the third-largest population in the nation. Experts credit local governments who issued stay-at-home orders prior to Governor Ron DeSantis’ statewide lockdown, as well as the elderly population who self-quarantined from the start. Even as the state enters phase 1 of its reopening, testing will continue to expand, with pharmacies now being allowed to administer tests and blood donations being randomly sampled for antibodies.
Last week, the FDA issued an emergency use declaration for remdesivir to treat patients with COVID-19, but why certain hospitals were picked to receive it and others passed over concerns many, STAT News notes. Many physicians and medical professionals complain about a lack of consensus surrounding the criteria needed to qualify to receive the drug while those who are set to receive it express concern there won’t be enough for their patients or nearby hospitals and medical centers. Originally developed by Gilead Sciences to treat the Ebola virus, the drug is still considered investigational and is not approved or licensed for use in any country. The supply being used to treat patients with COVID-19 is limited, coming from what is not needed for clinical research.
With some states slowly starting to try and return to business as usual, the CDC’s “Guidance for Implementing the Opening Up America Again Framework” will not be available to help guide their decisions, The Associated Press says. Meant to assist businesses, faith leaders, child care providers and educators, among many others, the 17-page document was originally slated for release on Friday, May 1. The report quoted someone close to the the coronavirus task force saying that CDC leadership had not cleared the release of the guidance, which is not mandatory. This news comes as President Donald Trump has deferred to letting states decide when they want to reopen, while those same states are seeking science-backed guidance to help them make the most informed decisions on doing so.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More